CDK5 and hepatocellular carcinoma: To evaluate whether the STAT3-HIF1α-DHHC7 loop could be a therapeutic target in vivo, we used the HIF1α inhibitor (echinomycin) and the DHHC7 inhibitor for further study, because inhibitors targeting on STAT3(26) and CDK5 (dinaciclib)(27, 28) had been proved effective in mice with HCC respectively.